#USA #Woburn #HCC #Sirtex #SIR-Spheres®

Introduction

In an impressive leap for cancer treatment, Sirtex Medical, a leader in interventional oncology, has unveiled remarkable findings from its DOORwaY90 study, aimed at patients suffering from unresectable hepatocellular carcinoma (HCC). The study revealed outstanding effectiveness with SIR-Spheres®, a revolutionary Yttrium-90 (Y-90) selective internal radiation therapy, achieving a stunning 100% local tumor control rate among participants after a full year.

Study Overview

Conducted as the inaugural pivotal and multicenter trial in the United States regarding this method, the DOORwaY90 study set ambitious performance metrics. It successfully met its co-primary endpoints with an impressive 90% complete response (CR) rate and an overall response rate (ORR) peaking at 99%, as confirmed by independent reviews. With no evaluable patients showing a lack of response, the results are celebrated as among the highest recorded outcomes in Y-90 therapies.

The durability of these responses is equally compelling; an astonishing 75% of the patients maintained their responses for over six months, culminating in a median response duration of 295 days. These findings underscore the potential of SIR-Spheres® Y-90 resin microspheres to induce long-lasting tumor responses while simultaneously preserving liver function, a crucial aspect given the context of the treatment.

Preservation of Liver Function

Over 95% of participants also showed stable liver function after 12 months, a testament to the tailored dosimetry approach employed in the study. The ability to deliver aggressive therapeutic responses without jeopardizing hepatic reserve is pivotal for practitioners aiming to enhance patients' outcomes while mitigating potential side effects.

Key Takeaways from the Presentation

This latest data was prominently showcased during a late-breaking presentation at the Society of Interventional Radiology (SIR) Annual Meeting held in Toronto, Canada. Dr. Armeen Mahvash, an interventional radiologist at MD Anderson Cancer Center and Co-Principal Investigator of this vital study, emphasized the consistent response rates achieved, fueling increased confidence in radioembolization as a promising option for aggressive tumor management in liver-directed therapies.

Reaction from Sirtex Medical

Matt Schmidt, the CEO of Sirtex Medical, stated, "The DOORwaY90 results elevate expectations for patients undergoing Y-90 therapy. With an exceptional overall response rate of 99% and total tumor control, this study demonstrates the power of personalized dosimetry, reshaping our approaches to liver treatments for those with unresectable HCC."

The Uniqueness of SIR-Spheres

Interestingly, SIR-Spheres® Y-90 resin microspheres stand alone as the sole FDA-approved radioembolization solution for treating both metastatic colorectal cancer (mCRC) and unresectable HCC within the United States. This status not only highlights the wide-ranging utility of this therapeutic approach but also emphasizes its pivotal role in modern oncological practice.

Conclusion

For healthcare professionals looking to expand their treatment toolkit for HCC patients, SIR-Spheres present a groundbreaking step forward. The DOORwaY90 study's results beckon a new era of personalized cancer care, revealing the vast possibilities ahead in effectively combating hepatocellular carcinoma. For further information regarding SIR-Spheres and insights into integrating personalized dosimetry into clinical routines, practitioners are encouraged to reach out to Sirtex Medical directly at [email protected]

About Sirtex Medical

Sirtex Medical, with its headquarters in Woburn, Massachusetts, is committed to pioneering innovation in the field of minimally invasive oncology. With a global presence extending to Europe, Australia, and Asia, it continues to push boundaries in offering effective interventional solutions for cancer treatment. For additional information, please visit www.sirtex.com.